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Abstract
Background: This study aimed to assess the trends in the prevalence of electrocardiographic (ECG) abnormalities
from 1986 to 2015 and impact of ECG abnormalities on risk of death from cardiovascular diseases (CVD) in the
Lithuanian population aged 40–64 years.
Methods: Data from four surveys carried out in Kaunas city and five randomly selected municipalities of Lithuania
were analysed. A resting ECG was recorded and CVD risk factors were measured in each survey. ECG abnormalities
were evaluated using Minnesota Code (MC). Trends in age-standardized prevalence of ECG abnormalities were
estimated for both sexes. Multivariate Cox proportional hazards models were used to estimate hazard ratios (HR) for
coronary heart disease (CHD) and CVD mortality. Net reclassification index (NRI), integrated discrimination
improvement and other indices were used for evaluation of improvement in the prediction of CVD and CHD
mortality risk after addition of ECG abnormalities variable to Cox models.
Results: From1986 to 2008, the decrease in the prevalence of Q-QS MC was observed in both genders. The
prevalence of high R waves increased in men, while the prevalence of ST segment and T wave abnormalities as
well as arrhythmias decreased in women. Ischemic changes and possible MI were associated with a 2.5-fold and
4.4-fold higher risk of death from CVD in men and 1.51-fold and 2.56-fold higher mortality risk from CVD in women
as compared to individuals with marginal or no ECG abnormalities. The addition of ECG abnormalities to traditional
CVD risk factors improved Cox regression models performance. According to NRI, 18.6% of men were correctly
reclassified in CVD mortality prediction model and 25.2% of men - in CHD mortality prediction model.
Conclusions: the decreasing trends in the prevalence of ischemia on ECG in women and increasing trends in the
prevalence of left VH in men were observed. ECG abnormalities were associated with higher risk of CVD mortality.
The addition of ECG abnormalities to the prediction models modestly improved the prediction of CVD mortality
beyond traditional CVD risk factors. The use of ECG as routine screening to identify high risk individuals for more
intensive preventive interventions warrants further research.
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Background
Cardiovascular diseases (CVD) are the main cause of death
accounting for about one third of all deaths among both
genders globally [1]. Deaths rates from CVD in Lithuania,
a country of Eastern Europe, are significantly higher than
in Northern, Southern and Western Europe countries
[2]. In 2014, age-standardized mortality rate from CVD
was 303.3 per 100,000 Lithuanian men aged 25–64 years
as compared to 96.8 per 100,000 men in European Union
countries. In women of the same age group, the difference
in CVD mortality rate between Lithuania and EU was also
high (75.0 and 32.1 per 100,000 women, respectively) [3].
The electrocardiography (ECG) is a routine, accessible,
inexpensive, and non-invasive tool for diagnosis of CVD.
Previous studies have reported that abnormalities on
resting ECG have been independently associated with
increased CVD risk [4–8]. However, the usefulness of
ECG in screening of asymptomatic adults is still debat-
able because clinical implications of ECG abnormalities
are unclear in low risk individuals [9]. Current evidence
is insufficient to assess the benefits of ECG as screening
tool in a population with high cardiovascular risk. Epi-
demiological studies carried out in Lithuanian adult
population showed high prevalence of traditional CVD
risk factors and ECG abnormalities [10, 11]. Considering
this situation, incorporation of ECG abnormalities in
CVD risk prediction might be useful in Lithuanian popu-
lation. To date, few studies have analysed the improve-
ment of CVD risk prediction adding ECG abnormalities
to traditional CVD risk factors [12, 13].
Therefore, the aim of the present study was to esti-
mate the trends in the prevalence of ECG abnormalities
from 1986 to 2015 and the impact of ECG abnormalities
on risk of death from CVD in the Lithuanian population
aged 40–64 years.
Methods
Study sample
Four cross-sectional surveys of random samples represent-
ing the Lithuanian population aged 40–64 years were
performed in 1986–1987, 1992–1993, 1999–2002, and
2006–2008. The surveys were carried out in Kaunas city
and five municipalities of Lithuania from the northern,
southern, eastern, western, and central regions of the coun-
try (Joniskis, Kaisiadorys, Kretinga, Kupiskis, and Varena).
For each survey, an independent random sample, stratified
by age and sex, was drawn from the Kaunas population
register and from the lists of the individuals registered at
the primary health care centres of municipalities. The se-
lected individuals were invited to health examination send-
ing them the invitation letters by mail. The response rates
in the five cross-sectional surveys were 70.2, 69.6%, 58.6,
62.4, and 58.1% respectively. Participants with missing or
inadequate ECG data (1.2%, similar numbers in all surveys)
were excluded. Respondents with clinically diagnosed
documented acute myocardial infarction (MI) were also
excluded from analysis (the proportion of excluded re-
spondents was 7.5% (8.5, 6.0, 7.1, 6.5, and 7.0% in the
respective surveys). In total, data of 11,904 individuals
(5427 men and 6477 women) were analysed.
All four studies were approved by the Lithuanian Regional
Bioethics Committee. All participants signed informed con-
sent form. Data of individual participants were not reported.
Measurements
The measurements were taken in outpatient departments
by the team consisting of trained doctors and nurses. In
each survey, the measurements were performed using the
same methodology. BP was measured twice from the right
brachial artery with a standard mercury sphygmomanom-
eter in the sitting position after 5 min of rest. Arterial
hypertension (AH) was defined as systolic BP ≥140mmHg
and/or diastolic BP ≥90mmHg, or BP < 140/90mmHg
taking antihypertensive medication for the last two weeks
before medical examination.
Weight and height were measured with a stadiometer
and a calibrated medical scale, without shoes and wear-
ing light indoor clothing. Body mass index (BMI) was
calculated as the ratio of weight (in kilograms) divided
by the square of height (in meters) (kg/m2). A BMI
within 18.5–24.99 kg/m2 was classified as normal weight,
while a BMI within 25.0–29.99 kg/m2 was considered as
overweight and participants with BMI ≥ 30.0 kg/m2 were
classified as obese.
Fasting (at least 12 h) venous blood specimens were
taken to determine lipid levels that were measured in
blood serum by conventional enzymatic method in the
certified laboratories. Dyslipidemias were defined as:
high total cholesterol level – higher than or equal to
5.0 mmol/L; high low density lipoprotein (LDL) choles-
terol level – higher than or equal to 3.0 mmol/L; low high
density (HDL) cholesterol level – lower than 1.0mmol/L
for men and lower than 1.2mmol/L for women, elevated
triglycerides level – higher than or equal to 1.7mmol/L.
Participants were classified as regular smokers (smoked
at least one cigarette per day) and others.
A resting electrocardiogram was recorded in the 12 stand-
ard leads, with the calibration of 10mm per 1mV and paper
speed of 25mm per second. ECG records were read by 2 in-
dependent experienced coders (trained cardiologists) using
the 1982 edition of the Minnesota Code (MC) [14]. Discrep-
ancies between two coders were resolved by a senior coder
(experienced cardiologist). The ECG findings were classified
into 6 large groups [15]: 1) Q-QS waves – MC 1.1–1.3; 2)
major ST segment and T wave changes – MC 4.1–4.3 or
MC 5.1–5.3; 3) high R waves – MC 3.1 or MC 3.3; 4) left
axis deviation – MC 2.1; 5) arrhythmias – MC 8.1–8.6
or MC 8.9 or MC 6.1–6.2 or MC 6.4 or MC 6.8; 6)
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blocks – MC 7.1 or MC 7.2 or MC 7.4. For further
analysis, clinically meaningful combinations of ECG ab-
normalities were considered: 1) definite MI – MC 1.1
or MC (1.2 + 5.1 or 5.2); 2) possible MI - MC 1.3 +MC
5.1 or MC 5.2; or MC 1.2 alone; 3) left ventricular
hypertrophy (VH) – MC 3.1 or 3.3 + any MC 4.1–4.3 or
5.1–5.3; 4) ischemia – MC 1.3 or MC 4.1–4.3 or MC 5.1–
5.3; 5) marginal or no ECG abnormalities – all other codes.
The five categories were hierarchically produced from the
most to the least severe.
Follow up data of the individuals from Kaunas surveys
were used for analysis of associations between ECG ab-
normalities and CHD or CVD mortality risk (n = 6090).
Deaths were identified from the regional mortality regis-
ter. Causes of death were coded by versions 9 and 10 of
the International Classification of Diseases (ICD): CVD
mortality included codes 390–458 of ICD-9 and I00-I99
of ICD-10; deaths from CHD included codes 410–414
of ICD-9 and I20-I25 of ICD-10. During period of
1986–2015, there were 1058 death cases from any cause,
503 deaths from CVD and 311 deaths from CHD.
Statistical analysis
The statistical software package IBM SPSS Statistics 20
and the R statistical software were used for data analysis
separately for men and women. We applied data weight-
ing adjustment technique to match the age distribution
of the Lithuanian population aged 40–64 years in 2008.
The differences in age-adjusted means of variables be-
tween the surveys and between men and women were
assessed using ANOVA analysis with Bonferroni mul-
tiple comparison test. A chi-squared test and z test with
Bonferroni corrections were used for assessing the differ-
ences in categorical variables. P < 0.05 values were consid-
ered statistically significant.
Hazard ratios (HR) and 95% confidence intervals (CI)
were estimated by the multivariate Cox proportional
hazards regression for CVD and CHD mortality. First of
all, HRs were calculated for five categories of clinically
meaningful combinations of ECG abnormalities with
adjustment for study number and CVD risk factors, such
as age, AH, smoking, HDL cholesterol, LDL cholesterol,
triglycerides, and BMI. Later, the predictive ability of
Cox regression Model 1, which included only above
mentioned CVD risk factors, was compared with predictive
ability of the Model 2 extended by ECG abnormalities.
ECG abnormalities were categorized into two groups – 1)
absent or marginal ECG abnormalities and 2) any of clinic-
ally meaningful ECG abnormality. The additional predictive
value of the models was determined using log-likelihood ra-
tio (likelihood ratio test - LRT). Lower P values indicated
larger difference between predictive quality of the models.
The incremental prognostic impact of the new predictor
(ECG abnormality) was estimated with Harrel’s C statistic,
integrated discrimination improvement (IDI), and the net
reclassification improvement index (NRI) [16, 17]. Harrel’s
C statistic is an established measure of model discrimin-
ation for binary outcomes and is assessed by calculating the
area under the receiver-operating characteristic curve. IDI
is a relatively independent of risk thresholds and categories
measure of the ability of the extended model to improve
average sensitivity without compromising average specifi-
city. NRI was calculated to determine the extent to which
incorporation of additional variable into the prediction
models improve the reclassification of individuals. IDI and
NRI were calculated at 10 years of follow-up.
Results
Age-standardized prevalence of ECG abnormalities among
Lithuanian men and women aged 40–64 years is presented
in Table 1. The prevalence of Q-QS codes significantly de-
creased from 4.1% in 1986–1987 to 2.1% in 2006–2008 in
men and from 3.2 to 2.1% in women. In men, the preva-
lence of left axis deviation and high R waves showed a
significant increase between the first and last survey, while
no significant trends in those abnormalities were found
in women. A significant decrease in the prevalence of ST
segment and T wave abnormalities and arrhythmias in
women was observed from 1986 to 1987 to 2006–2008.
In the majority of the surveys, the prevalence of ST seg-
ment and T wave abnormalities was significantly higher in
women than men, while the prevalence of other ECG abnor-
malities was higher in men compared to women (Table 1).
Analysis of clinically meaningful ECG abnormalities
showed that the prevalence of left VH in men increased
from 3.1% in 1986–1987 to 5.8% in 2006–2008, whereas
the prevalence of ischemia in women decreased from
12.3 to 5.9% during the same period.
Age-standardized mean levels and the prevalence of
main risk factors among men and women were analysed
using the pooled data from all surveys (Tables 2 and 3).
The men with definite MI were older than men with
marginal or absent ECG abnormalities. They had higher
mean total and LDL cholesterol levels and lower level of
systolic BP as compared to men with left VH. In men
with ischemia, mean levels of systolic and diastolic BP,
BMI and triglycerides were higher than in men with
marginal or absent ECG abnormalities.
The women with definite MI had higher means of
systolic and diastolic BP as compared to women with is-
chemia and marginal or no ECG abnormalities (Table 3).
The highest level of LDL cholesterol was observed in
women with ischemia. Moreover, those women had higher
BMI, total cholesterol and triglycerides than women
having marginal or no ECG abnormalities.
Cox regression analysis was used to calculate the inde-
pendent contribution of clinically meaningful ECG abnor-
malities to the risk of dying from CVD and CHD when
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other conventional risk factors had been accounted for
(Table 4). Follow up period started from the health
examination date and finished on 31st of December, 2015.
The mean duration of follow-up was 12.8 + 7.79 years
(12.5 + 7.82 years in men and 13.1 + 7.75 years in women).
In men, ischemic changes on ECG and possible MI were
associated with a 2.5-fold and 4.4-fold higher risk of death
from CVD as compared to men with marginal or absent
of ECG abnormalities (reference group). Risk of dying
from CVD was 1.51-fold higher in women with ischemia
and 2.56-fold higher in women with possible MI than in
reference group. A similar impact of clinically meaningful
ECG abnormalities on CHD mortality was observed in
men but not in women (Table 4).
For comparison of predictive ability of Cox regression
models, the dichotomized variable (any clinically meaning-
ful ECG abnormality and absent of abnormality) was used.
Risk of CVD and CHD mortality was significantly higher
in men and women having any clinically meaningful ECG
abnormality (Table 5). The addition of ECG abnormal-
ities had some effect on Cox regression models per-
formance. According to the LRT tests, the extension
of the Model 1 by mentioned variable significantly im-
proved the performance of model in both genders. A
slight increase in Harrell’s C-statistic was observed,
once the variable of ECG abnormalities was added to
other risk factors in the models for CVD and CHD
mortality. In men, the values of IDI were 1.3% (p = 0.007)
for CVD mortality and 1.0% (p < 0.001) for CHD mortality,
which suggests a modest improvement in discrimination of
the Cox regression models when ECG abnormalities were
added to the models. In women, the respective values of
IDI were lower than in men. Addition of ECG abnormal-
ities to the model adjusted for traditional CVD risk factors
resulted in reclassification of 18.6% of men in CVD mortal-
ity prediction model and 25.2% of men in CHD mortality
prediction model. No net reclassification improvement was
observed in women.
Table 1 Age-standardized prevalence of ECG abnormalities in Lithuanian population aged 40–64 years
Prevalence of ECG abnormalities Study years P from chi
squared1986–1987 1992–1993 1999–2002 2006–2008
Men (n) 1496 926 1119 1886
Q - QS codes, % 4.1 3.8* 2.5* 2.1a 0.002
Left axis deviation, % 4.3* 5.5* 3.3 5.2* 0.048
ST-T codes, % 6.3* 3.8a, * 5.0* 5.1 0.057
High R waves, % 6.3* 5.8* 9.0a, b, * 9.5a, b, * < 0.001
Arrhythmia, % 5.3 5.9 4.7* 4.4* 0.295
Blocks, % 1.4 1.4* 1.8* 1.8* 0.729
Definite myocardial infarction, % 1.2* 1.0* 0.8* 0.5* < 0.001
Possible myocardial infarction, % 1.2 1.1 0.7 0.7*
Left ventricular hypertrophy, % 3.1 4.0* 6.3 a, * 5.8 a, *
Ischemia, % 5.9* 4.0* 4.0* 4.7
Marginal abnormalities or absent, % 88.6* 89.8 88.1 88.3*
Women (n) 1609 1114 1415 2339
Q - QS codes, % 3.2 1.8 1.1a 2.1 < 0.001
Left axis deviation, % 2.8 2.8 2.2 2.7 0.696
ST-T codes, % 12.9 7.7a 9.1a 5.9a, c < 0.001
High R waves, % 4.2 2.7 3.7 3.5 0.233
Arrhythmia, % 4.8 4.2 2.6a 3.1a 0.004
Blocks, % 0.7 0.5 0.6 0.8 0.869
Definite myocardial infarction, % 0.4 0.0 0.2 0.2 < 0.001
Possible myocardial infarction, % 1.4 0.6 0.4a 1.4c
Left ventricular hypertrophy, % 2.6 1.7 2.1 2.2
Ischemia, % 12.3 8.2a 8.4a 5.9a, c
Marginal abnormalities or absent, % 83.2 89.5a 88.9a 90.3a
ap < 0.05 compared to 1986–1987, Bonferroni test. bp < 0.05 compared to 1992–1993, Bonferroni test. cp < 0.05 compared to 1999–2002, Bonferroni test. *p < 0.05
compared men to women
ECG: electrocardiogram
Bold typeface of P values indicates significance
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Discussion
This study describes the trends in the prevalence of ECG
abnormalities and the prognostic impact of these abnor-
malities on risk of death from CHD and CVD in Lithuania
over a period of more than two decades. To our knowledge,
our study is the first to describe trends in the prevalence
and prognostic impact of ECG abnormalities coded by MC
not only in Lithuania but also in all Baltic countries.
Over the study period, we observed a significant in-
crease in the prevalence of left VH in male population.
These findings might be explained by the data of our
previous studies carried out during the same period
showing the increasing trends in the prevalence of AH
among middle-aged Lithuanian men [11]. Other investiga-
tors demonstrated that effective antihypertensive treat-
ment might result in regression of left VH [18, 19]. In
Lithuania, however, the proportion of controlled AH still
remains rather low, especially among men, despite some
improvement in AH management [20].
During 20 years period, the prevalence of ischemia
among women decreased. The observed positive trends
might be associated with a significant decrease in the preva-
lence of dyslipidemias and obesity in Lithuanian women
between 1986 and 2006 [11]. The positive changes in lipid
levels could be related to the changes in nutrition habits of
Lithuanians that were more pronounced in women. Our
previous study demonstrated the increase in the use of
vegetable oil for cooking and replacement of butter spread
with margarine, also the decrease in consumption of high
fat milk [21]. Moreover, the National CVD Prevention
Programme for high risk individuals was introduced in
Lithuania in order to improve the control of CVD risk fac-
tors [22]. The reduced prevalence of ischemia on ECG of
women was associated with decreasing trends in CVD
mortality among Lithuanian women between 1985 and
2013 [11]. In men, the reduction of CVD mortality was
observed only from 2008. These changes could be at-
tributed to a combination of long-term increase in in-
come, other socio-economic changes, improvements in
health care and dietary changes.
In our study, the prevalence of ECG abnormalities, with
exception of ST-T codes, was significantly higher in men
than in women. Similar gender differences in the preva-
lence of major and minor ECG abnormalities were found
in the adult population of Reykjavik and in the Hispanic
Community Health Study [6, 23]. However, in the Chicago
Heart Association Detection Project the prevalence rates
of major ECG abnormalities were higher in women than
in men, while minor ECG abnormalities were more com-
mon in men compared to women [24].
Table 2 Age-standardized mean values and prevalence of risk factors in men by ECG abnormality group
ECG abnormalities
Mean values and prevalence Definite MI Possible MI Left VH Ischemia Marginal or absent P from Anova
n = 45 n = 51 n = 263 n = 258 n = 4810
Age, years, mean (SD) 54.7 (6.49) 53.9 (6.25) 51.3a (7.44) 54.2c (6.88) 51.1a,b,d (6.87) < 0.001
Systolic BP, mmHg, mean (SD) 142.9 (25.7) 152.1 (32.) 153.2a(25.4) 154.7 a (24.5) 142.7b,c,d (20.9) < 0.001
Diastolic BP, mmHg, mean (SD) 91.3 (13.0) 94.7 (21.4) 97.4 (13.0) 96.6 (14.0) 91.3c,d (12.4) < 0.001
BMI, kg/m2, mean (SD) 27.6 (4.82) 29.0 (4.43) 27.2 (4.04) 29.2 c (4.78) 27.6d (4.56) < 0.001
Total cholesterol, mmol/L, mean (SD) 6.29 (1.21) 6.12 (1.31) 5.73a (1.16) 6.03 (1.23) 5.88 (1.20) 0.007
LDL cholesterol, mmol/L, mean (SD) 4.27 (1.16) 4.00 (1.08) 3.63a (1.13) 3.92 (1.11) 3.81 (1.17) 0.006
HDL cholesterol, mmol/L, mean (SD) 1.26 (0.27) 1.17 (0.33) 1.39b (0.39) 1.27 c (0.45) 1.35 (0.43) 0.001
Triglycerides, mmol/L, mean, (SD) 1.37 (0.58) 2.04a (1.73) 1.63 (0.93) 1.83 (1.12) 1.62d (1.02) 0.001
P from χ2
Arterial hypertension, % 63.3 82.4 80.5 83.3a 64.7c,d < 0.001
Regular smoking, % 35.6 25.5 37.8 41.1 39.7 0.274
Total cholesterol > 5.0 mmol/L, % 86.0 87.2 71.5 79.3 76.9 0.045
LDL cholesterol > 3.0 mmol/L, % 88.6 86.0 66.9 82.7c 75.4c < 0.001
HDL cholesterol < 1.0 mmol/L, % 16.7 32.6 11.1b 29.1c 19.5c, d < 0.001
Triglycerides > 1.7 mmol/L, % 26.2 48.9 37.4 44.6 34.1d 0.002
Normal weight, BMI < 25.0 kg/m2, % 29.5 13.7 29.0 19.4 29.2d < 0.001
Overweight, BMI 25.0–29.9 kg/m2,% 50.0 47.1 48.5 42.2 44.7
Obesity, BMI > 30.0 kg/m2, % 20.5 39.2 22.5 38.4c 26.1d
ap < 0.05 compared to definite MI group, Bonferroni test. bp < 0.05 compared to possible MI group, Bonferroni test. cp < 0.05 compared to left VH group,
Bonferroni test, dp < 0.05 compared to left VH group, Bonferroni test. BMI body mass index, BP blood pressure, ECG electrocardiogram, HDL high-density
lipoproteins, MI myocardial infarction, LDL low-density lipoproteins, SD standard deviation, VH ventricular hypertrophy
Bold typeface of P values indicates significance
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We found lower mean levels of systolic and diastolic
BP, some lipids and BMI in men and women with mar-
ginal or absent ECG abnormalities as compared to indi-
viduals having ECG abnormalities. Our data is in line
with the findings from other studies where the preva-
lence and mean levels of most CVD risk factors were
higher in individuals with major and minor ECG abnor-
malities as compared to those without such abnormal-
ities [25–28]. On the other hand, the prevalence of ECG
abnormalities has been found higher in individuals with
CVD risk factors [29].
After adjustment for the main CVD risk factors, male
participants of our study with ischemia and possible MI
based on ECG abnormalities had a significantly higher
risk of CVD and CHD mortality as compared to men
with marginal or absent ECG abnormalities. In women,
the same ECG abnormalities were associated only with
higher risk of CVD mortality; moreover, HRs were lower
Table 4 Adjusteda hazard ratios of CVD and CHD mortality by group of clinically meaningful electrocardiographic abnormalities and
sex
CVD mortality CHD mortality
ECG abnormality Men n = 281 Women n = 167 Men n = 172 Women n = 96
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Marginal abnormalities or absent 1.0 – 1.0 – 1.0 – 1.0 –
Ischemia 2.50 (1.67–3.74) < 0.001 1.51 (1.00–2.27) 0.048 2.00 (1.14–3.51) 0.016 1.67 (0.99–2.82) 0.053
Left VH 1.65 (0.94–2.91) 0.082 1.19 (0.52–2.72) 0.686 1.58 (0.77–3.25) 0.211 1.09 (0.34–3.50) 0.885
Possible MI 4.40 (2.30–8.42) < 0.001 2.56 (1.03–6.35) 0.042 4.83 (2.21–10.55) < 0.001 3.04 (0.94–9.86) 0.064
(2.30–8.42) (1.03–6.35) (2.21–10.55) (0.94–9.86)
Definite MI 1.94 (0.48–7.91) 0.355 3.75 (0.50–27.93) 0.197 2.83 (0.68–11.68) 0.151 6.81 (0.88–52.76) 0.066
a - adjusted for age, education, arterial hypertension, high density lipoprotein cholesterol, low density lipoprotein cholesterol, body mass index, smoking, and
study number. CI confidence interval, CHD coronary heart disease, CVD cardiovascular diseases, ECG electrocardiogram, HR hazard ratio, MI myocardial infarction,
VH ventricular hypertrophy. Bold typeface indicates significance
Table 3 Age-standardized mean values and prevalence of risk factors in women by ECG abnormality group
ECG abnormalities
Mean values and prevalence Definite MI Possible MI Left VH Ischemia Marginal or absent P from Anova
n = 14 n = 69 n = 584 n = 105 n = 5705
Age, years, mean (SD) 53.0 (6.40) 51.0 (7.41) 54.3b (6.66) 53.9b (6.62) 50.9c,d (6.91) < 0.001
Systolic BP, mmHg, mean (SD) 168.9 (38.9) 150.3 (28.2.) 162.5b (27.1) 146.3a,c (25.8) 139.1a,b,c,d (22.8) < 0.001
Diastolic BP, mmHg, mean (SD) 98.8 (19.0) 91.4 (14.4) 97.0b (13.7) 90.2c (13.0) 87.5a,c,d (12.1) < 0.001
BMI, kg/m2, mean (SD) 32.3 (6.79) 30.1 (5.14) 31.3 (6.28) 30.2 (5.71) 29.2c,d (5.63) < 0.001
Total cholesterol, mmol/L, mean (SD) 5.68 (1.08) 5.78 (1.39) 6.14 (1.21) 6.40b (1.47) 5.99d (1.27) < 0.001
LDL cholesterol, mmol/L, mean (SD) 3.12 (0.99) 3.56 (1.29) 3.95 (1.19) 4.22a,b (1.39) 3.83d (1.21) < 0.001
HDL cholesterol, mmol/L, mean (SD) 1.66 (1.02) 1.41 (0.39) 1.51 (0.41) 1.47 (0.41) 1.51 (0.41) 0.072
Triglycerides, mmol/L, mean, (SD) 1.49 (0.77) 1.53 (1.00) 1.54 (0.74) 1.60 (0.95) 1.45d (0.77) 0.001
P from χ2
Arterial hypertension, % 85.7 68.2 86.2b 65.0c 55.4c,d < 0.001
Regular smoking, % 21.4 8.7 7.0 5.7 9.1 0.030
Total cholesterol > 5.0 mmol/L, % 76.9 72.1 85.9 85.3 78.6d 0.001
LDL cholesterol > 3.0 mmol/L, % 54.5 70.0 77.3 82.9 74.6d 0.001
HDL cholesterol < 1.0 mmol/L, % 41.7 32.3 21.5 25.2 22.3 0.072
Triglycerides > 1.7 mmol/L, % 25.0 24.2 31.3 34.5 28.5 0.065
Normal weight, BMI < 25.0 kg/m2, % 7.7 17.1 15.6 19.7 24.2 < 0.001
Overweight, BMI 25.0–29.9 kg/m2,% 23.1 30.0 30.0 31.1 36.3
Obesity, BMI > 30.0 kg/m2, % 69.2 52.9 52.9 53.9 39.5c,d
ap < 0.05 compared to definite MI group, Bonferroni test. bp < 0.05 compared to possible MI group, Bonferroni test. cp < 0.05 compared to left VH group,
Bonferroni test, dp < 0.05 compared to left VH group, Bonferroni test. BMI body mass index, BP blood pressure, ECG electrocardiogram, HDL high-density
lipoproteins, MI – myocardial infarction, LDL low-density lipoproteins, VH ventricular hypertrophy
Bold typeface of P values indicates significance
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than in men. Our results are similar to those obtained
in other population studies that analysed gender dif-
ferences in prognostic values of ECG abnormalities
and showed lower CVD mortality risk in women than
in men [24, 30]. However, other authors did not find
any gender differences in predicting CVD mortality
risk for ECG abnormalities [31–34].
Pathological Q waves in the absence of documented MI
are important cardiac abnormalities detected through
ECG screening. Those patients do not receive medical
treatments that could prevent adverse outcomes, in-
cluding recurrent MI or CVD death [35]. Cohort stud-
ies demonstrated that Q/QS wave abnormalities (silent MI)
were associated with increased risk of CHD and all-cause
mortality [36–38]. Prognostic values of those ECG ab-
normalities have been shown to be similar to clinically
documented MI.
Nonspecific ST segment and T wave abnormalities
were related to CVD and CHD mortality in asymptom-
atic older and middle-aged persons [32, 39–41]. It was
suggested that those ECG abnormalities might indicate
subclinical CHD.
Several studies reported that ECG left VH was a pre-
dictor of multiple CVD outcomes (sudden cardiac death,
MI, congestive heart failure and stroke) [25, 42]. Accord-
ing to results of the LIFE study, regression of ECG left VH
during antihypertensive treatment was associated with
better CVD outcomes [18]. Contrary to those findings, we
did not estimate an association between left VH and mor-
tality from CVD and CHD. Similar results were found in
the study conducted in three European countries [15].
Possible explanation could be an adjustment of mortality
HRs for AH which is strongly related with left VH.
Our results demonstrated that resting ECG abnormalities
significantly improved the prediction of CVD and CHD
mortality beyond traditional cardiovascular risk factors. In
men, the addition of ECG abnormalities resulted in reclassi-
fication of 18.6 and 25.2% of participants when risk of dying
from CVD and CHD was assessed. Only few studies ana-
lysed the changes in the predictive ability of Cox models
after the addition of resting ECG abnormalities [12, 13].
The results of Health, Aging, and Body Composition Study
(Health ABC Study) showed that 13.6% participants with
minor and major ECG abnormalities were correctly reclas-
sified when ECG abnormalities were added [39]. However,
in studies carried out in Netherlands and Norway, inclu-
sion of ECG abnormalities did not improve models per-
formance [13, 43].
Some limitations should be considered when interpret-
ing our findings. Only a single ECG tracing was recorded
for each participant during the baseline examination. It is
recognized that single ECG record, same as other single
biologic measurements, could lead to underestimation of
the impact of examined factors on risk due to misclassifi-
cation [44]. The low prevalence of some ECG abnormal-
ities could be another limitation of our study. A relatively
small number of deaths within ECG categories may limit
the power to demonstrate the association between ECG
abnormalities and mortality risk. Moreover, we have no
information about changes in participants’ health be-
haviours, biologic CVD risk factors, and ECG during
observation period. These changes might have impact
on risk of mortality from CVD. Finally, the response
rates lower than 70% might have resulted in selection
bias and potential underestimation of the prevalence of
ECG abnormalities, if non-response was associated with a
more adverse risk profile. However, it is unlikely that the
strength of this association has changed substantially be-
tween the surveys. This assumption together with the
relatively similar response rates over time minimizes the
potential impact of non-response on our estimates of the
trends in the prevalence of ECG abnormalities.
Table 5 Comparison of models for prediction of CVD and CHD mortality without and with addition of electrocardiographic
abnormalities
ECG CVD mortality CHD mortality
abnormalities Men n = 281 Women n = 167 Men n = 172 Women n = 96
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
No – 1 – 1 – 1 – 1
Yes – 2.34 (1.72–3.19) – 1.56 (1.09–2.24) – 2.15 (1.44–3.22) – 1.71 (1.07–2.73)
Harrell‘s C 0.704 0.730 0.803 0.814 0.715 0.745 0.829 0.842
LRT (p-value) – 24.62 (< 0.001) – 5.48 (0.019) – 12.02 (< 0.001) – 4.79 (0.029)
IDI (p-value) – 0.013 (0.007) – 0.004 (0.040) – 0.010 (< 0.001) – 0.004 (0.173)
NRI (p-value) – 0.186 (0.007) – 0.186 (0.153) – 0.252 (0.027) – 0.212 (0.206)
Model 1 – factors included into model: age, education, arterial hypertension, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides,
body mass index, smoking; Model 2 – variables of Model 1 plus ECG abnormalities
CHD coronary heart disease, CI confidence interval, CVD cardiovascular diseases, HR hazard ratio, IDI integrated discrimination improvement, LRT likelihood ratio
test, NRI net reclassification index
Bold typeface indicates significance
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The strength of our study includes the large number
of participants from middle-aged Lithuanian population
and long-term follow up. To our knowledge, this is the
first report on the trends in ECG abnormalities and im-
pact of these abnormalities on risk of death from CHD
and CVD in Lithuania and other Baltic countries. The
standardized ECG procedures and carefully documented
registration of death events during follow up were used.
Multiple lifestyle and biological CVD risk factors were
assessed using uniform collection of data. This allowed
to make adjustments for a large number of potential
confounding variables in the Cox models.
Conclusions
In 1986–2008, the decreasing trends in the prevalence of
ischemia on ECG in women and increasing trends in the
prevalence of left VH in men were observed. ECG abnor-
malities were associated with higher risk of CVD mortality
and modestly improved the prediction of CVD mortality
beyond traditional CVD risk factors. Given the wide avail-
ability, low cost and safety, the ECG might be used to im-
prove CVD risk prediction and to identify the individuals
for more intensive preventive interventions. Further stud-
ies are needed to ascertain whether ECG should be incor-
porated in routine screening.
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